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TO THE EDITOR IN CHIEF - In the recent systematic review and meta-analysis by Lansbury et al. only 7% of 1 
hospitalised patients with COVID-19 were reported as having evidence of bacterial co-infection, yet >90% received 2 
empirical antibiotics 1. This finding, which has been replicated elsewhere2, is hardly surprising given the challenges 3 
associated with distinguishing bacterial from viral pneumonia and that bacterial coinfection is likely to worsen an 4 
already poor prognosis in these patients3. Whilst the role of biomarkers such as procalcitonin is being explored, a 5 
desire to treat what is treatable is understandable but represents a threat to antibiotic stewardship45. In their 6 
study, Lansbury et al. found that bacterial coinfection was more common for those in intensive care (ICU) (14%, 7 
95% CI 5-26, vs 4%, 95% CI 1-9) but only one study provided data on the timing of infection in relation to 8 
admission. Distinguishing between bacterial co-infection acquired prior to or following ICU admission is essential 9 
when developing antibiotic prescribing policies. 10 
 11 
Some of the concern over bacterial co-infection in COVID-19 stems from experience with influenza where 12 
bacterial co-infection is well-recognised and often the factor precipitating admission to ICU.6 Experience is 13 
growing that the same is not true for COVID-197. Whilst any patient on ICU is vulnerable to nosocomial infection, 14 
we observe that- in contrast to influenza- bacterial co-infection at ICU admission is rare. 15 
 16 
Table 1 presents microbiologically-confirmed bacterial co-infection findings from a subset of patients enrolled 17 
into the ongoing AspiFlu study (www.isrctn.com/ISRCTN51287266). Ventilated adults with confirmed SARS-CoV-18 
2 or influenza infection that had >1 respiratory tract sample sent for culture were included in this analysis. 19 
Bacterial co-infection was defined as either i) positive urinary antigen test; ii) culture of pathogen from 20 
blood/bronchoalveolar lavage (BAL) fluid; or iii) positive endotracheal aspirate culture with suggestive 21 
radiology(e.g. focal/ lobar consolidation), neutrophilia and clinician-instigated antibiotic treatment. 22 
 23 
In the influenza cohort, early (<48h hours of ICU admission) bacterial co-infection was common, 14/24 (58%), and 24 
caused by community-acquired pathogens such as Streptococcus pneumoniae, Staphylococcus aureus, 25 
Haemophilus influenzae and Streptococcus pyogenes (Group A strep) in 7/14. In contrast, early co-infection was 26 
uncommon in the COVID-19 cohort 3/36 (8%, P<0.0001). The incidence of late (>48h of ICU admission) co-27 
infection in COVID-19 did not significantly differ from influenza (36% vs. 50%, p=0.3) and in 12/13 cases was 28 
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caused by gram negative bacteria commonly associated with ventilator-associated pneumonia (VAP) and 29 
catheter-related bloodstream infection1. Important differences between the groups were that the influenza 30 
cohort had a shorter duration of symptoms before ICU admission (5 vs 9 days, p=0.002) and a higher proportion 31 
received Extra Corporeal Membrane Oxygenation (46% vs 0%, P<0.0001) and BAL sampling (79% v 8%, P<0.0001). 32 
Interestingly, the influenza cohort had better survival despite worse baseline SOFA/APACHE 2 scores. 33 
 34 
For the purposes of antibiotic stewardship, COVID-19 is not like influenza. Most patients with COVID-19 present 35 
to ICU with a viral pneumonitis rather than bacterial co-infection. More work is needed on strategies and 36 
biomarkers to help identify those most likely to benefit from antibiotics. Whilst clinicians must remain vigilant 37 
about nosocomial infection, we advocate against routine empiric antibiotic use in patients hospitalised with 38 
COVID-19 infection. Courses of empirical antibiotics initiated whilst SARS-CoV-2 test results are pending should 39 
be promptly reviewed upon having the diagnosis of COVID-19 confirmed. Antibiotics should only be continued for 40 
those with a presentation suggestive of bacterial coinfection (e.g. productive cough, focal consolidation, 41 
neutrophilia) or supportive positive microbiology.4 A narrow spectrum antibiotic should be used wherever 42 
possible, informed by local guidance and microbiology results. It can be especially difficult to withhold antibiotics 43 
from patients with COVID-19 cytokine release syndrome, which can mimic bacterial sepsis. In such patients, the 44 
ongoing need for antibiotics should be continuously reviewed in light of response to immunomodulatory therapy 45 
and limited to as short a duration as possible. The impact of immunomodulatory therapies such as corticosteroids 46 
(now standard of care for ventilated patients in light of  RECOVERY trial findings 8), anti-cytokine antibodies and 47 
JAK inhibitors (currently being investigated 9,10) on bacterial coinfection warrants further study. Future research 48 
could also explore whether the rate of nosocomial infection in ICU patients with COVID-19 was artificially high at 49 
the peak of the pandemic when challenging working environments and shortages of PPE may have impeded 50 
optimal infection prevention and control practice. 51 
 52 
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Patient characteristics     
Age, median (IQR) 56 (47-63) 59 (51-65) p=0.29 
Male, n (%) 15 (63%) 25 (69%) p=0.59 
Severe immunosuppression, n (%) 2 (8%) 2 (6%) P>0.99 
Systemic corticosteroids last 21 days, n (%) 7 (29%) 4 (11%) p=0.097 
Chronic Lung Disease, n (%) 7 (29%) 4 (11%) p=0.097 
Chronic Kidney Disease, n (%) 1 (4%) 3 (8%) p=0.64 
Diabetes, n (%) 4 (17%) 12 (33%) p=0.23 
Hypertension, n (%) 5 (21%) 13 (36%) p=0.26 
Active / Past Smoker, n (%) 11 (46%) 14 (39%) p=0.61 
Duration of symptoms (days), median (IQR) 5 (2-7) 9 (6-11) p=0.0018 
Admission SOFA score, median (IQR) 10 (9-13) 6 (4-8) p<0.0001 
Admission APACHE 2 score, median (IQR) 22 (17-27) 14 (11-19) p<0.0001 
Lymphocyte: Neutrophil ratio, median (IQR) 112 (7-20) 13 (6-18) p=0.85 
Diagnostic sampling, no of patients (%)    
Respiratory tract sampling 24 (100%) 36 (100%) p>0.99 
Bronchoalveolar lavage 19 (79%) 3 (8%) P<0.0001 
Urine legionella Antigen 19 (79%) 30 (83%) p=0.74 
Urine pneumococcal Antigen  20 (83%) 27 (75%) p=0.53 
Blood culture 24 (100%) 36 (100%) p>0.99 
Mycoplasma serology/PCR 20 (83%) 7 (19%) P<0.0001 
Interventions and Outcomes    
Renal replacement therapy, n (%) 15 (63%) 15 (42%) p=0.19 







Days ventilated, median (IQR) 16 (9-28) 18 (12-27) p=0.62 
Days on ICU, median (IQR) 22 (16-32) 20 (16-31) p=0.97 
90 day all-cause mortality, n (%) 4 (17%) 18 (50%) p=0.013 
Bacterial coinfection      




(8%)  P<0.0001 




(36%)  p=0.30 
Gram positive Early Late  Early Late  
Streptococcus pneumoniae 2 0 0 0  
Staphylococcus aureus 2 0 1 1  
Streptococcus pyogenes (Group A Strep) 2 0 0 0  
Enterococci 0 1 1 0  
Gram negative Early Late  Early Late  
Haemophilus influenzae 1 1 0 0  
Coliforms 1 5 0 9  
Pseudomonas 1 1 0 1  
Other 5 4 1 2  
Influenza; A not subtyped (n=9), H1N1 (n=10), H3N2 (n=4), B (n=1). Coliforms; Klebsiella, Escherichia coli, Citrobacter, Enterobacter, 
Serratia. Other; Proteus, Stenotrophomonas, polymicrobial. Respiratory tract sampling; sputum, bronchoalveolar lavage, non-directed 
lavage, endotracheal aspirate. p values calculated using Fisher's exact test for categorical and Mann-Whitney U test for continuous 
variables using GraphPad Prism 8.4.2. SOFA/Apache 2 scores calculated using www.mdcalc.com. 
